Latest Pharmacy News

EZZ Life Science Holdings marked a pivotal quarter with the launch of its EZZDAY brand in the US, a significant Southeast Asia distribution agreement, and expanded domestic retail presence, driving a 46% jump in customer receipts.

Epsilon Healthcare has emerged from voluntary administration with a stronger balance sheet, securing refinancing and preparing to launch its new pharmacy platform. Operational stability and strategic initiatives signal a turning point for the healthcare group.

Nuchev Limited reports a record-breaking Q4 FY25 with revenues soaring 167% year-on-year, driven by strong growth across multiple markets and a strategic agency agreement in Australia.

Aumake Limited reports a robust 50% revenue increase to $39 million for FY25, driven by improving China-Australia trade relations. The company unveils a strategic pivot and corporate restructuring to sharpen its focus on profitable growth and brand incubation.

Firebrick Pharma has published positive Phase 3 clinical trial results for its Nasodine nasal spray, showing efficacy against the common cold, while reporting encouraging sales growth in Singapore and the US. However, a recent capital raise fell well short of targets, casting uncertainty over its expansion plans.

McPherson’s Limited anticipates FY25 revenue around $139 million with a strong second-half EBITDA rebound, while its strategic shift to third-party wholesalers sets the stage for significant EBIT gains in FY26.

Immuron Limited reports a robust 49% increase in FY25 global sales of its immune supplement Travelan, driven by strong growth in Australia and North America. The company plans to accelerate its North American market presence in FY26.

Biome Australia Limited has reported a 69% increase in international sales revenue for FY25, reaching $1.5 million, driven by new strategic distribution agreements across Ireland, New Zealand, and Canada.

Tissue Repair Limited has secured major distribution partnerships in Australia, New Zealand, and Thailand for its TR Pro+® product line, marking a pivotal shift from development to commercialisation. The company is also scaling up manufacturing and advancing regulatory approvals to support its global expansion ambitions.

Pharmx Technologies has extended its pivotal National Diabetes Services Scheme agreement and expanded its supplier base, reinforcing its leadership in pharmacy digital infrastructure across Australia and New Zealand.

MedAdvisor Limited has finalized the sale of its Australian and New Zealand operations to Jonas Software for an estimated $42.35 million, marking a strategic pivot towards its US business. The company also announced upcoming CFO changes as it refocuses its growth trajectory.

MedAdvisor Limited has entered a binding agreement to sell its ANZ business division and intellectual property to Jonas Software for a headline price of $35 million plus an uncapped earn-out. The deal marks a strategic pivot as MedAdvisor focuses on its US operations.